Furthermore, upregulation of CD80, CD86, and CD83 on LPS-stimulated DCs was not modified by the addition of melanoma CM, suggesting that at least in our experimental model, the secretome of melanoma cells, either sensitive or resistant to vemurafenib, did not interfere with the activation of DCs mediated by PAMPS (data not shown). This evidence concerns the gene CD86 and melanoma.